LIPID STATUS IN CHILDREN WITH CHRONIC PYELONEPHRITIS
https://doi.org/10.24884/1561-6274-2017-3-75-80
Abstract
THE AIM: to study the lipid status in children with secondary pyelonephritis with its various currents.
PATIENTS AND METHODS: 80 children with secondary chronic pyelonephritis were observed. Lipid profile was determined on the AU 400 OLYMPUS (BECKMAN COULTER Inc., USA). To detect foci nephrosclerosis conducted nephroscintygraphy. Statistical data processing was performed using program «Statistica 6.1».
RESULTS: in 60% of children total cholesterol level (TC) remained in the range of low risk, 25% were in the moderate-risk group (LDL 4,4-5,15 mmol/l) and 15% had a high cardio-vascular risk (LDL more than 5,18 mmol/l). We found no significant differences in lipid profile in children with frequent and rare relapses of the disease and also in children with dismetabolic and obstructive pyelonephritis.
CONCLUSION: patients with signs of nephrosclerosis had increased total cholesterol level.
About the Authors
O. V. Nesterenko
Saratov State Medical University n.a. V.I.Rasumovsky
Russian Federation
Russian Federation
MD, PhD, Department of Faculty pediatrics,
410012, Saratov, Bolshaya Kazachya st., 112
V. M. Popkov
Saratov State Medical University n.a. V.I.Rasumovsky
Russian Federation
Russian Federation
Prof., MD, PhD, DMedSci., Department of Urology,
410012, Saratov, Bolshaya Kazachya st., 112
V. B. Borodulin
Saratov State Medical University n.a. V.I.Rasumovsky
Russian Federation
Russian Federation
MD, PhD, DMedSci., Department of Biochemistry,
410012, Saratov, Bolshaya Kazachya st., 112
V. I. Goremykin
Saratov State Medical University n.a. V.I.Rasumovsky
Russian Federation
Russian Federation
MD, PhD, DMedSci., Department of Biochemistry,
410012, Saratov, Bolshaya Kazachya st., 112
E. V. Komarova
Saratov State Medical University n.a. V.I.Rasumovsky
Russian Federation
Russian Federation
MD, Clinical-diagnostic laboratory of Clinical hospital of S.R. Mirotvortsev,
410054, Saratov, Bolshaya Sadovaya st., 137.
E. V. Bobyleva
Saratov State Medical University n.a. V.I.Rasumovsky
Russian Federation
Russian Federation
MD, PhD, Department of Biochemistry,
410012, Saratov, Bolshaya Kazachya st., 112
References
1. Игнатова МС, ред. Детская нефрология. ООО «Медицинское информационное агентство», М., 2011; 696 с. [Ignatova MS, red. Detskaja nephrologija. OOO “MIA”, М., 2011; 696 p.]
2. Лучанинова ВН. К дискуссии о хронической болезни почек и тубулоинтерстициальных нефропатиях в педиатрической нефрологии. Педиатрия 2008; 87(3):131-134 [Luchaniniova VN. K diskussii o hronicheskoj bolezni pochek i tubulointersticialnyh nephropatijah v pediatricheskoj nephrologii. Pediatrija 2008;87(3):131-134]
3. Паунова СС. Патогенетические основы нефросклероза. Нефрология и диализ 2005;7(2):130-135 [Paunova SS. Patogeneticheskije osnovy nephrosclerosa. Nephrologija i dializ 2005;7(2):130-135]
4. Невструева ВВ, Клембовский АИ, Харина ЕА и др. Клинические и патогенетические проблемы нарушенной клеточной энергетики. М., 1999. [Nevstrueva VV, Klembovskij AI, Harina EA i dr. Klinicheskije i patogeneticheskije problemy narushennoj kletochnoj energetiki. М., 1999]
5. Колина ИБ. Гиперлипидемии при хронической болезни почек: особенности и подходы к лечению. Лечащий врач 2012; (1) [Kolina IB. Giperlipidemii pri hronicheskoj bolezni pochek: osobennosti i podhody k lecheniju. Lechashij vrach 2012; (1)]
6. Fine LG, Bandyopadbay D, Norman GT. Kidney Int 2000; 57 (Suppl. 75):22-26
7. Jeppe Hagstrup Christensen, Erik Berg Schmidt. N-3 Polyunsaturated Fatty Acids, Lipids and Lipoproteins in End-stage Renal Disease. Clin Lipidology 2011; 6 (5): 563–576
8. Игнатова МС, Шатохина ОВ. Клинико-генетические аспекты диагностики нефропатий у детей. Нефрология и диализ 2003; (1):8-14. [Ignatova MS, Shatohina OV. Kliniko-geneticheskije aspekty diagnostiki nephropatij u detej. Nephrologija I dializ 2003; (1):8-14]
9. Charles R Harper, Terry A Jacobson. Managing Dyslipidemia in Chronic Kidney Disease. J Am CollCardiol 2008; 51 (25): 2375–2384
10. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60(5):850-886
11. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2011; 376 (9740): 540–550
12. Grundy S, De Groot LJ, Chrousos G et al. Risk Assessment and Guidelines for the Management of High Blood Cholesterol. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. 2000-2015 Jun 12
13. Waters DD LDL-cholesterol lowering and renal outcomes. Curr Opin Lipidol 2015 Jun; 26(3):195-9. doi: 10.1097/MOL.0000000000000176
14. Смирнов АВ. Клиническое и прогностическое значение дислипидемий у больных ХГН. Дис. … д.м.н. СПб 1997; 244 [Smirnov AV. Klinicheskoje I prognosticheskoje znachenije dislipidemij u bolnyh HGN. Dis. … d.m.n. SPb1997; 244]
15. Колина ИБ. Статины при хронической болезни почек: безопасность применения. Эффективная фармакотерапия. Урология и нефрология. Спец. Выпуск 2012; 62-68 [Kolina IB. Statiny pri hronicheskoj bolezni pochek: bezopasnost primenenija. Effektivnaja farmakoterapija. Urologija I nephrologija. Spez. vypusk2012; 62-68]
16. Рекомендации по профилактике сердечно-сосудистых заболеваний в детском и подростковом возрасте. Российский кардиологический журнал, №6 (98)–2012, приложение 1, с. 23-28 [Rekomendacii po profilaktike serdechno-sosudistyh zabolevanij v detskom I podrostkovom vozraste. Rossijskij kardiologicheskij jurnal, №6 (98) – 2012, prilojenije 1, с. 23-28
17. Mirjam Harmsen, Michel Wensing, Jozé CC Braspenning, René J Wolters, Johannes C van der Wouden, Richard PTM Grol. Management of children’s urinary tract infections in Dutch family practice: a cohort study. BMC Family Practice 2007; (8):9
18. Hussein A, Askar E, Elsaeid M, Schaefer F.Functional polymorphisms in transforming growth factor-beta-1 (TGFbeta-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection. Nephrol Dial Transplan 2010;25(3):779-85
19. Lundstedt AC, McCarthy S, Gustafsson MC-U et al. A genetic basis of susceptibility to acute pyelonephritis. PLoS ONE 2007;(2):825doi:10.1371/journal.pone. 0000825
20. Wong MG, Wanner C, Knight J, Perkovic V. Lowering cholesterol in chronic kidney disease is it safe and effective? Eur Heart J 2015 Nov 14;36(43):2988-95. doi: 10.1093/eurheartj/ehv393
21. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potentialconsequences. Am J Physiol Ren Physiol 2005; 290: 262–272
22. Banach M, Aronow WS, Serban MC et al. Lipids, blood pressure and kidney update 2015. Lipids Health Dis 2015 Dec 30; 14:167. doi: 10.1186/s12944-015-0169-0
23. Marks SD, Gordon I, Tullus K. Imaging in childhood urinary tract infections: time toreduce investigations. Pediatr Nephrol 2008;23(1):9-17
Review
For citations:
Nesterenko O.V., Popkov V.M., Borodulin V.B., Goremykin V.I., Komarova E.V., Bobyleva E.V. LIPID STATUS IN CHILDREN WITH CHRONIC PYELONEPHRITIS. Nephrology (Saint-Petersburg). 2017;21(3):75-80. (In Russ.) https://doi.org/10.24884/1561-6274-2017-3-75-80
Views:
7885
Email this article 